Duavee Back In Stock With Improved Packaging
Posted on June 06, 2023
Duavee® (conjugated estrogens/bazedoxifene) is back in stock at pharmacies with improved packaging!
In 2020, Pfizer voluntarily recalled Duavee due to a weakness in the secondary packaging. Secondary packaging ensures that oxygen doesn’t reach the product and protects the product’s shelf life. Duavee was NOT recalled due to safety issues with the tablets themselves.
Pfizer conducted an investigation and evaluated potential solutions, testing each against a series of thresholds. Duavee packaging has been updated to include a new insert called an O2 scavenger, which prevents oxygen from breaching the primary packaging.
Duavee® (conjugated estrogens/bazedoxifene) is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus:
- Treatment of moderate to severe vasomotor symptoms associated with menopause
- Prevention of postmenopausal osteoporosis
Limitations of Use
Duavee should be used for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
For more information, please visit duavee.pfizerpro.com.